Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan.
PMID: 32873061
2021
AIDS research and human retroviruses
Abstract: In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs, with the most common mutations of M184V/I (49.1%; 52/106), K65R (18.9%; 20/106), K103N (23.6%; 25/106), and G190S (22.6%; 24/106).
Rapid HIV-1 drug resistance testing in a resource limited setting: the Pan Degenerate Amplification and Adaptation assay (PANDAA).
PMID: 34795836
2021
The Pan African medical journal
Result: Besides DRMs assessed by PANDAA (K65R, M184V, K103N, Y181C and G190A), additional major DRMs to NRTI (L74I, D67N, K70E and K219R) were found in 3/120 participants (3%), as follows: L74I in combination with M184V were found in 2/120 participants (2%) and D67N +K70E+219R together with M184V occurred in 1 participant (1%).
Result: Pre-treatment drug resistance (K65R, M184V,
[HIV-1 drug resistance and subtypes in newly reported HIV/AIDS patients before antiretroviral therapy in Taizhou city, 2016-2018].
PMID: 34814456
2021
Zhonghua liu xing bing xue za zhi
Abstract: The resistance mutations of NNRTIs and NRTIs were mainly K103 N (0.7%) and M184I/V (0.5%).
Human Immunodeficiency Virus (HIV) Drug Resistance, Phylogenetic Analysis, and Superinfection Among Men Who Have Sex with Men and Transgender Women in Sub-Saharan Africa: HIV Prevention Trials Network (HPTN) 075 Study.
Abstract: Major drug resistance mutations were detected in samples from 21 (14.6%) of 144 participants; the most frequent mutations were K103N and M184V/I.
Genetic Diversity and Acquired Drug Resistance Mutations Detected by Deep Sequencing in Virologic Failures among Antiretroviral Treatment Experienced Human Immunodeficiency Virus-1 Patients in a Pastoralist Region of Ethiopia.
Abstract: Among NRTI resistance mutations, M184V (73.2%), K219Q (63.4%) and T215 (56.1%) complex were the most mutated positions, while the most common NNRTI resistance mutations were K103N (24.4%), K101E, P225H and V108I 7.5% each.
Result: Among NRTI resistance mutations, M184V (73.2%), and K219Q, (63.4%) were the most common resistance mutations detected from viraemic subjects, respectively.
Table: M184V
Discussion: A recent global research conducted in an attempt to find a point of care genotypic resistance test to detect HIV-1 drug resistance
HIV Pretreatment Drug Resistance Trends in Mexico City, 2017-2020.
Result: The most commonly observed DRMs were K103NS (24.1%) and M184VI (23.3%) in RT.
Discussion: Taking this into consideration, most ADR cases observed in the present study could still be associated with failures to offer efavirenz-based first-line regimens in persons who had not yet switched to INSTI-based options, which is also consistent with the high frequency of K103NS and M184VI observed in persons with ADR.
Evaluation of doravirine-based regimen population target in a large Italian clinical center.
Abstract: Additionally, we experimentally simulated previously reported ETV/3TC resistance for HBV using HIVY115F/F116Y/Q151M with F160M/M184V (L180M/M204V in HBV RT) substituted.
Abstract: Structural analysis of RTY115F/F116Y/Q151M/F160M/M184V:DNA:3TC-TP also demonstrated that the loosely bound 3TC-TP is misaligned at the active site to prevent a steric clash with the side chain gamma-methyl of Val184.
Introduction: 3TC is also approved as an anti-HIV-1 agent, and M184V in HIV-1 RT, which co
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
PMID: 32065630
2020
The Journal of antimicrobial chemotherapy
Abstract: BACKGROUND: M184V/I NRTI resistance mutations can be selected by either lamivudine/emtricitabine or abacavir.
Abstract: CONCLUSIONS: M184V/I as a unique NRTI resistance mutation, regardless of possible selection by regimens containing lamivudine/emtricitabine or abacavir, does not affect the virological response of well-controlled patients who switched to abacavir/lamivudine/dolutegravir for at least 12 months.
Abstract: OBJECTIVES: We assessed the efficacy of abacavir/lamivudine/dolutegravir when used in HIV-infected pretreated patients with an undetectable VL who previously harboured M184V/I as a unique NRTI resistance mutation in a genotypic resistance test and had no resistance to
High resistance to reverse transcriptase inhibitors among persons infected with human immunodeficiency virus type 1 subtype circulating recombinant form 02_AG in Ghana and on antiretroviral therapy.
Discussion: M184 V also increases susceptibility to Zidovudine, Stavudine, and Tenofovir, and is associated with a clinically significant reduction in HIV-1 replication in vivo.
Discussion: Due to the decrease in susceptibility, patients infected with HIV-1 with the M184 V mutation continue treatment with Lamivudine, resulting in continuous exposure, and consequently, higher frequency of the mutation.
Discussion: Supplementary Digital Content 3) has been shown previously.M184 V mutation causes high-level resistance to Lamivudine, and therefore the high frequency of the mutation observed in this study is not unusual since the drug is the most common NRTI in use in Ghana.
Discussion: The predominance of M184 V and D67N among mutations associated with resistance to
HIV mutation literature information.
PMID: 
2021
AIDS research and human retroviruses
Browser Board
Co-occurred Entities
Filtrator
ViMRT